Ablynx Competitors and Similar CompaniesClear all
Ablynx's competitors and similar companies include ImmunoGen and Innate Pharma.
 Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. |  ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. |  Innate Pharma Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. | |
Founding Date | Founding Date 2001 | Founding Date 1981 | Founding Date 1999 |
Type | Type Subsidiary | Type Public | Type Public |
Tags | |||
Locations | Locations Gent, BE HQ | Locations Waltham, US HQ | Locations Marseille, FR HQ Rockville, US |
Employees | Employees 1252% decrease | Employees 277161% increase | Employees 181 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 8.7 b | Valuation ($) 148.6 m |
Financial | |||
Revenue (est.) | Revenue (est.) €85.2m (FY, 2016) | Revenue (est.) $108.8m (FY, 2022) | Revenue (est.) €2.8m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $176k (FY, 2022) | Cost of goods €266k (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $108.6m (FY, 2022) | Gross profit €8.7m (FY, 2025) |
Net income | Net income (€1.1m) (FY, 2016) | Net income ($222.9m) (FY, 2022) | Net income (€49.2m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 498.8m | Total funding raised $ 56m | Total funding raised $ 94.1m |
For sources of this data, please see the company profile
View Company Profiles
ImmunoGen
HQ
Waltham, US
Employees
277
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
View companyInnate Pharma
HQ
Marseille, FR
Employees
181
Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
View company